Medicare AdvantageCoverageMedium impact
MA08.073q, Intravitreal Injection of Vascular Endothelial Growth Factor (VEGF) Antagonists, VEGF Biosimilars, and Combination VEGF/Angiopoietin-2 (Ang-2) Inhibitors
Independence Blue Cross·Ophthalmology·Pharmacy
Effective date
Jan 1, 2025
We identified it
Jun 19, 2026
Summary
Medical necessity criteria for intravitreal injection of VEGF antagonists, VEGF biosimilars, and combination VEGF/Angiopoietin-2 inhibitors have been updated for Medicare Advantage plans. This policy change affects billing and coverage requirements for these eye injections used to treat conditions like macular degeneration and diabetic retinopathy.
Action Required
Before January 1, 2025: Billing team and ophthalmology providers must review updated medical necessity criteria for VEGF antagonist intravitreal injections. Update prior authorization workflows and documentation requirements for Medicare Advantage patients receiving these treatments. Ensure clinical documentation meets new medical necessity standards to prevent claim denials.